Study explores faecal calprotectin for neonatal calf diarrhoea
Bottom line
A new study in Veterinary Record Open suggests faecal calprotectin could help identify gastrointestinal inflammation in neonatal calves with diarrhoea, even when measured with a human ELISA kit. The researchers reported that diarrhoeic calves had significantly higher faecal calprotectin concentrations than healthy controls, alongside lower albumin-to-globulin ratios, and found associations between calprotectin, faecal score, and serum biochemical markers. The work adds to a small but growing body of cattle research exploring whether a biomarker widely used in human gastroenterology can translate into calf medicine. (sciencedirect.com)
Why it matters: For veterinary professionals, the study points to a potentially useful non-invasive marker for intestinal inflammation in neonatal calf diarrhoea, a syndrome that remains a major welfare and production problem in the first month of life. But the findings are still early-stage: neonatal calf diarrhoea has multiple infectious and management-related causes, and prior work in cattle has focused more on assay validation than on routine clinical deployment. That means faecal calprotectin is best viewed, for now, as an adjunctive research or referral-lab marker rather than a replacement for clinical scoring, hydration assessment, pathogen testing, and serum biochemistry. (bvajournals.onlinelibrary.wiley.com)
What to watch: The next step is whether larger field studies establish clinically useful cutoffs, species-specific validation, and evidence that calprotectin testing changes treatment decisions or outcomes in calves. (sciencedirect.com)
Key facts
- Study
- Assessment of faecal calprotectin in neonatal calf diarrhoea using a human ELISA kit
- Journal
- Veterinary Record Open
- Population
- Neonatal calves with diarrhoea
- Test
- Human ELISA kit for faecal calprotectin
- Main finding
- Diarrhoeic calves had significantly higher faecal calprotectin concentrations than healthy controls
- Associated findings
- Lower albumin-to-globulin ratios, and associations with faecal score and serum biochemical markers
- Interpretation
- Faecal calprotectin may help identify gastrointestinal inflammation in neonatal calf diarrhoea
A new calf study is testing whether an established human gut-inflammation marker can fill a diagnostic gap in bovine neonatology. In Veterinary Record Open, investigators assessed faecal calprotectin in neonatal calf diarrhoea using a human ELISA kit and found higher concentrations in diarrhoeic calves than in healthy controls, with additional associations to faecal score and serum biochemical changes. (sciencedirect.com)
That matters because neonatal calf diarrhoea is still one of the most important early-life disease syndromes in cattle, with consequences for welfare, treatment use, labor, growth, and mortality. It’s also a complex syndrome rather than a single disease entity: common infectious contributors include rotavirus, Cryptosporidium parvum, coronavirus, E. coli, and, less commonly, Salmonella, while management, colostrum status, and coinfections shape severity and outcomes. (bvajournals.onlinelibrary.wiley.com)
The appeal of calprotectin is straightforward. In human medicine, faecal calprotectin is widely used as a non-invasive marker of intestinal inflammation because it reflects neutrophil activity in the gut. Veterinary researchers have been exploring whether that biology carries over to food animals and companion animals. Prior bovine work has already shown that calves with diarrhoea tend to have higher faecal calprotectin, and a 2023 validation study found a human-origin immunoturbidimetric assay suitable for bovine fecal samples, with clinical validation showing higher concentrations in diarrhoeic calves. (sciencedirect.com)
The new paper appears to push that literature a step further by linking faecal calprotectin not just to diarrhoea status, but also to faecal scoring and serum biochemical markers, including a lower albumin-to-globulin ratio in affected calves. That’s potentially useful because clinicians already interpret diarrhoeic calves through a combination of stool character, hydration, acid-base and electrolyte derangements, and systemic illness markers. A biomarker that tracks intestinal inflammation could, in theory, help distinguish calves with more active enteric inflammatory disease from those with looser feces but less mucosal involvement. (onlinelibrary.wiley.com)
There’s also broader assay context behind the headline. Recent bovine biomarker studies have emphasized method validation, matrix effects, and the impact of fecal water content. A 2025 comparative study reported that fecal calprotectin was less affected by fecal moisture than lactoferrin, which may be an advantage in diarrhoeic samples, but it also underlines that assay choice, extraction method, and species-specific validation remain important before routine clinical adoption. Human gastroenterology guidance similarly stresses consistency of platform and extraction method when interpreting calprotectin results over time. (sciencedirect.com)
Expert reaction specific to this paper was not readily available in public sources at the time of writing, but the direction of travel in the literature is clear: researchers are treating faecal calprotectin as a promising inflammation marker, not yet a stand-alone diagnostic. That distinction matters in calf practice, where the main clinical questions are often practical ones, including whether a calf needs oral versus parenteral fluids, whether septicemia is a concern, whether a herd problem warrants pathogen workup, and how prevention should be adjusted. (sciencedirect.com)
Why it matters: For veterinary professionals, this study is less about an immediately practice-ready test and more about a possible future tool for stratifying diarrhoeic calves. If further validated, faecal calprotectin could support earlier recognition of intestinal inflammation, enrich clinical trials, or help referral and herd-health teams compare severity across cases and outbreaks. But the bar for adoption is higher than statistical significance alone: clinicians will need assay standardization, age-appropriate reference intervals, practical turnaround times, cost clarity, and evidence that results improve case management beyond what’s already gained from examination, fecal scoring, and targeted diagnostics. (sciencedirect.com)
What to watch: Watch for larger prospective studies, pathogen-stratified analyses, and validation of species-appropriate cutoffs, especially studies that test whether calprotectin predicts severity, treatment intensity, or outcomes in calves with neonatal diarrhoea. (sciencedirect.com)